Boostrix, Repevax, Biltricide and Rhythmodan are facing supply tensions in France. Sinking and exceptional imports are all symptomatic treatments for a fundamental problem.
Boostrix and Repevax: tension reminder vaccines
Boostrix (Glaxosmithkline) and Repevax (Sanofi) vaccines, widely used for immunization against diphtheria, tetanus, darling and polio, are currently in city supply. These vaccines, administered from the age of 3 years as a reminder, are also used for passive protection of the infant when vaccination is carried out during pregnancy.
Due to this situation, the two laboratories have set up a quantitative quota limited to the city, sparing hospital establishments and ultramarine territories (DROM). The return to a normal distribution of Boostrix and Repevax is planned only for the end of December 2025.
Biltricide 600 mg: an exceptional provision from Kenya
Biltricide 600 mg (praziquantel), antiparasitic against bilharzia and distomatosis, has been out of stock since September 2024. To respond to this shortage, Bayer Healthcare SAS has organized an exceptional import from Kenya from 1is July 2025.
Although the composition is identical to that of the drug distributed in France, the packaging differs: the boxes contain 4 tablets instead of 6. Each box is provided with a counter-label in French and must be accompanied by a notice in French as well as an information letter for the patient. The product must be kept at a temperature below + 30 ° C. For any question, Bayer provides a toll -free number: 0800 87 54 54.
Rhythmodan LP 100 and 250 mg: persistent tensions on antiarrhythmic
Rhythmodan, used in the treatment of heart rate disorders, has been the subject of persistent supply difficulties since February 2024. To cope with the shortage of the LP 250 mg dosage, units had been temporarily imported from Belgium. The National Medicines Safety Agency (ANSM) also recommended to substitute with Rythmodan 100 mg when necessary. However, this alternative is no longer possible: the latter has also been out of stock since June 20, 2025. Under these conditions, the recommended substitution strategy becomes difficult to applicable. A partial discount is expected in mid-July 2025, according to the latest information available.
